Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

SALT LAKE CITY, May 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it has entered into license and supply agreement with Aché…

Lipocine Partners with Brazil Firm to Launch TLANDO®: A New Chapter in Global Expand Lipocine Inc., a prominent biopharmaceutical entity dedicated to pioneering treatments for men's health, has reached a significant milestone in its global outreach. The company has finalized a licensing and supply agreement for its testosterone replacement therapy, TLANDO®,with Brazil. This strategic alliance is designed to improve access to TLANDO® for Brazil i…